Thursday, 15 October 2026European Markets

SOC FRANC CASINOS Stock Over 17% Up So Far On Friday

Loading stream...

(vianews) - shares of soc franc casinos (cac 40: sfca.pa) rose by a staggering 17.32% to €2.10 at 14:10 est on friday, after five successive sessions in a row of losses. cac 40 is dropping 0.71% to €7,430.45, following the last session's upward trend. this seems, up until now, a somewhat bearish trend exchanging session today.

soc franc casinos's last close was €1.79, 11.39% below its 52-week high of €2.02.

about soc franc casinos

société française de casinos société anonyme operates casinos in france. the company is also involved in the hotel and restaurant activities. the company is based in paris, france.

earnings per share

as for profitability, soc franc casinos has a trailing twelve months eps of €0.3.

pe ratio

soc franc casinos has a trailing twelve months price to earnings ratio of 7. meaning, the purchaser of the share is investing €7 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.61%.

volatility

soc franc casinos's last week, last month's, and last quarter's current intraday variation average was a negative 11.73%, a negative 0.60%, and a positive 7.62%.

soc franc casinos's highest amplitude of average volatility was 11.73% (last week), 7.90% (last month), and 7.62% (last quarter).

yearly top and bottom value

soc franc casinos's stock is valued at €2.10 at 14:10 est, above its 52-week high of €2.02.

volume

today's last reported volume for soc franc casinos is 18 which is 90.76% below its average volume of 195.

moving average

soc franc casinos's value is way above its 50-day moving average of €1.83 and way higher than its 200-day moving average of €1.72.

more news about soc franc casinos (sfca.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com